The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing

@article{Ortuso2018TheMC,
  title={The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing},
  author={Francesco Ortuso and Donatella Bagetta and Annalisa Maruca and Carmine Talarico and Mar{\'i}a Laura Bolognesi and Norbert Haider and Fernanda Borges and Sharon D. Bryant and Thierry Langer and Hanoch Senderowitz and Stefano Alcaro},
  journal={Frontiers in Chemistry},
  year={2018},
  volume={6}
}
For every lead compound developed in medicinal chemistry research, numerous other inactive or less active candidates are synthetized/isolated and tested. The majority of these compounds will not be selected for further development due to a sub-optimal pharmacological profile. However, some poorly active or even inactive compounds could live a second life if tested against other targets. Thus, new therapeutic opportunities could emerge and synergistic activities could be identified and exploited… 

Figures from this paper

Computer-based techniques for lead identification and optimization I: Basics

TLDR
This chapter may be a useful manual of molecular modeling techniques used in the lead-optimization and lead identification processes.

Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors

TLDR
This work represents a starting point for the optimization of the most promising EOs structure as kinase inhibitors with multi-target features.

Identification of SET/EED dual binders as innovative PRC2 inhibitors.

TLDR
A multistage screening protocol highlighted the great potential of Chemotheca for identifying polypharmacological agents and identified five 1,2,3-triazole derivatives as promising dual EZH2/EED modulators.

Identification of New Potential Inhibitors of Quorum Sensing through a Specialized Multi-Level Computational Approach

TLDR
Multiple promising compounds were identified, yielding good prospects for future experimental validation and for drug repurposing towards QS inhibition, using CviR—the quorum-sensing receptor from Chromobacterium violaceum—as a model target.

Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.

TLDR
The discovery of 4-methyl-5-{4-[(4-sulfamoylphenyl)amino]phthalazin-1-yl}benzenesulfonamide as an inhibitor of human NPP3 identified by compound library screening is reported on.

Multi-targeted drug design strategies for the treatment of schizophrenia

TLDR
Current concepts of schizophrenia are summarized with the emphasis on the modern dopaminergic, serotoninergic, and glutamatergic hypotheses, and different aspects of design of multi-target ligands are covered, including the application of molecular modeling approaches for the design and benefits and limitations of multifunctional compounds.

Why promising drugs are shelved and barriers and facilitators to re-purposing them: A systematic literature review

TLDR
More research is needed on the current value of repurposing in drug development, as there remain uncertainties, as well as on how to better facilitate access to resources to support it, where valuable.

Drug repurposing: a systematic review on root causes, barriers and facilitators

TLDR
Promising drugs are commonly shelved due to insufficient efficacy or superiority to alternate therapies, poor market prospects, and industry consolidation, and more research is needed on the current value of repurposing in drug development.

In Silico Identification of Possible Inhibitors for Protein Kinase B (PknB) of Mycobacterium tuberculosis

TLDR
The optimization and application of an in silico computational protocol to find new PknB inhibitors led to the identification of six compounds for further experimental testing while also providing additional structural information for the design of more specific and more effective derivatives.

References

SHOWING 1-10 OF 17 REFERENCES

The ChEMBL bioactivity database: an update

TLDR
More comprehensive tracking of compounds from research stages through clinical development to market is provided through the inclusion of data from United States Adopted Name applications and a new richer data model for representing drug targets has been developed.

DrugBank: a comprehensive resource for in silico drug discovery and exploration

TLDR
DrugBank is a unique bioinformatics/cheminformatics resource that combines detailed drug data with comprehensive drug target information and is fully searchable supporting extensive text, sequence, chemical structure and relational query searches.

PubChem Substance and Compound databases

TLDR
An overview of the PubChem Substance and Compound databases is provided, including data sources and contents, data organization, data submission using PubChem Upload, chemical structure standardization, web-based interfaces for textual and non-textual searches, and programmatic access.

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

TLDR
A number of substructural features which can help to identify compounds that appear as frequent hitters (promiscuous compounds) in many biochemical high throughput screens are described.

Benchmarking sets for molecular docking.

TLDR
A directory of useful decoys (DUD), with 2950 ligands for 40 different targets, leading to a database of 98,266 compounds, which allowed 40x40 cross-docking, where the enrichments of each ligand set could be compared for all 40 targets, enabling a specificity metric for the docking screens.

ZINC: A Free Tool to Discover Chemistry for Biology

TLDR
The database contains over twenty million commercially available molecules in biologically relevant representations that may be downloaded in popular ready-to-dock formats and subsets and is freely available at zinc.docking.org.

DrugBank 5.0: a major update to the DrugBank database for 2018

TLDR
This year’s update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years and significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions.

Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS

TLDR
A large-scale analysis of the impact of PA INS alerts on compound promiscuity in bioassays using publicly available data in PubChem found that the majority (97%) of all compounds containing PAINS alerts were actually infrequent hitters in AlphaScreen assays measuring PPI inhibition.

Open Babel: An open chemical toolbox

TLDR
The implementation of Open Babel is detailed, key advances in the 2.3 release are described, and a variety of uses are outlined both in terms of software products and scientific research, including applications far beyond simple format interconversion.